Stereotactic Body Radiation Therapy After Chemotherapy for Unresectable Perihilar Cholangiocarcinoma (STRONG II)

Stereotactic Body Radiation Therapy After Chemotherapy for Unresectable Perihilar Cholangiocarcinoma: A Multicenter Phase II Trial (The STRONG 2 Trial)

The objective of this study is to evaluate the efficacy of stereotactic body radiation therapy (SBRT) as additional treatment after standard chemotherapy regarding tumor local control, toxicity, progression-free survival (PFS), overall survival and quality of life. In addition, the objective is to explore the value of immunodynamics in peripheral blood for predicting PFS in patients undergoing chemotherapy.

Study Overview

• Status: Recruiting
• Conditions: Klatskin Tumor
• Intervention / Treatment: Radiation: Stereotactic body radiation therapy

Detailed Description

Rationale:

For patients with perihilar cholangiocarcinoma, surgery is the only treatment modality that can result in cure. Unfortunately, in the majority of these patients the tumors are found to be unresectable at presentation due to local invasive tumor growth or the presence of distal metastases. For patients with unresectable cholangiocarcinoma, palliative chemotherapy is the standard treatment, yielding an estimated median overall survival of 12-15.2 months.

There is no evidence from randomized trials that support the routine use of stereotactic body radiation therapy (SBRT) for cholangiocarcinoma. The STRONG phase I feasibility study showed favorable outcomes regarding safety, and the therapy was generally well tolerated. Based upon these observations, a phase II multi-center study with SBRT after chemotherapy in patients with unresectable perihilar cholangiocarcinoma is proposed, in order to further research the efficacy of adding SBRT to standard chemotherapy.

In addition, an explorative translational research component is part of the study, in which peripheral immunodynamics, specifically myeloid nuclear factor kappa-light-chain enhancer of activated B cells (NF-kB) signaling and interferon-stimulated genes (ISG) responses within the myeloid cells, may help to predict survival after chemotherapy and may also help to predict the value of additional treatment with radiotherapy.

Objective:

The objective of this study is to evaluate the efficacy of SBRT as additional treatment after standard chemotherapy regarding tumor local control, toxicity, progression-free survival (PFS), overall survival and quality of life. In addition, to explore the value of immunodynamics in peripheral blood for predicting PFS in patients undergoing chemotherapy.

Study design:

Single-arm, multicenter phase II study.

Study population:

The initial translational part of the study will be performed in patients diagnosed with unresectable perihilar cholangiocarcinoma, 18 years of age or older, T1-4 N0-2 M0 (AJCC staging 8th edition), eligible for gemcitabine-based chemotherapy. Exclusion criteria are tumor extension into either stomach, colon, duodenum, pancreas or abdominal wall. After completion of chemotherapy and no local or distant progression during or after chemotherapy, the patients will proceed to SBRT if they are still eligible based on the inclusion and exclusion criteria. It may occur that patients do not give consent for the translational part of the study, but they may wish to participate in the SBRT part of the trial and vice versa. Sample size will be 30 patients.

Intervention:

SBRT will be delivered in 15 fractions of 4 to 4.5Gy after 8 cycles of chemotherapy. In case of toxicity causing premature termination of systemic treatment, the patient can still proceed to SBRT.

Main study parameters/endpoints:

The primary endpoint of this study is local tumour control, defined as time from inclusion to local radiological progression. Definition of progression is based on response evaluation criteria in solid tumours (RECIST) 1.1.

Secondary endpoints:

• Toxicity according to the Common Toxicity Criteria for Adverse Events (CTCAE) V.5.0 grading system.
• Biliary stent-related events (SRE).
• Progression-free survival defined as time from inclusion until radiological progression. Definition of progression is based on RECIST 1.1.
• Overall survival defined as time from inclusion until death from any cause.
• Quality of life (QoL), assessed by means of the EuroQol (EQ)-5D-5L (measure of health outcome in general population), and the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 (QoL specific for patients with cancer) with the supplementary module EORTC QLQ-BIL21 (specific for CCA and gallbladder cancer).

• Study Type: Interventional
• Enrollment (Estimated): 30
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Alejandra Méndez Romero, MD, PhD; Phone Number: +31 (0)10 7035792; Email: a.mendezromero@erasmusmc.nl
• Study Contact Backup: Name: Suus van Loosbroek, MSc; Email: s.vanloosbroek@erasmusmc.nl

Study Locations

• Belgium
  • Antwerp
    • Wilrijk, Antwerp, Belgium, 2610
      • Not yet recruiting
      • Antwerp University Hospital / Sint-Augustinus Gasthuiszusters
      • Contact: Prof. Ines Joye, MD, PhD; Email: ines.joye@gza.be
      • Principal Investigator: Prof. Ines Joye, MD, PhD
  • Brussels-capital
    • Brussels, Brussels-capital, Belgium, 1070
      • Not yet recruiting
      • University Hospital Brussels / Jules Bordet Institute
      • Contact: Christelle Bouchart, MD, PhD; Email: Christelle.Bouchart@bordet.be
      • Principal Investigator: Christelle Bouchart, MD, PhD
• Netherlands
  • Groningen, Netherlands, 9713 GZ
    • Recruiting
    • University Medical Center Groningen
    • Contact: Derk Jan de Groot, MD, PhD; Email: d.j.a.de.groot@umcg.nl
    • Principal Investigator: Derk Jan de Groot, MD, PhD
  • Utrecht, Netherlands, 3584 CX
    • Recruiting
    • University Medical Center Utrecht
    • Contact: Prof. Martijn Intven, MD, PhD; Email: m.intven@umcutrecht.nl
    • Principal Investigator: Prof. Martijn Intven, MD, PhD
  • Gelderland
    • Nijmegen, Gelderland, Netherlands, 6525 GA
      • Recruiting
      • Radboud University Medical Center
      • Contact: Harm Westdorp, MD, PhD; Email: harm.westdorp@radboudumc.nl
      • Principal Investigator: Harm Westdorp, MD, PhD
  • Limburg
    • Maastricht, Limburg, Netherlands, 6229 ET
      • Recruiting
      • Maastricht University Medical Center+ / Maastro Clinic Maastricht
      • Contact: Jeroen Buijsen, MD, PhD; Email: jeroen.buijsen@maastro.nl
      • Principal Investigator: Jeroen Buijsen, MD, PhD
  • Noord-Holland
    • Amsterdam, Noord-Holland, Netherlands, 1081 HV
      • Recruiting
      • Amsterdam University Medical Center
      • Contact: Eva Versteijne, MD, PhD; Email: e.versteijne@amsterdamumc.nl
      • Principal Investigator: Eva Versteijne, MD, PhD
  • Zuid-Holland
    • Rotterdam, Zuid-Holland, Netherlands, 3015 CD
      • Recruiting
      • Erasmus MC
      • Principal Investigator: Alejandra Méndez Romero, MD, PhD
      • Contact: Alejandra Méndez Romero, MD, PhD; Phone Number: +31 (0)10 7035792; Email: a.mendezromero@erasmusmc.nl

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion criteria translational part of the study:

In order to be eligible to participate in the translational part of the study, a subject must be discussed in a liver tumor board, should be eligible for gemcitabine-based chemotherapy (and immunotherapy, if applicable), and should meet all of the following criteria pre-chemotherapy:

• Perihilar cholangiocarcinoma (pCCA) according to the criteria of the Mayo Clinic, Rochester: a positive or strongly suspicious intraluminal brush cytology or biopsy, or a radiographic malignant appearing stricture plus either: CA 19-9>100 U/ml in the absence of acute bacterial cholangitis, or polysomy on fluorescence in situ hybridization (FISH), or a well-defined mass on cross sectional imaging
• One tumor mass
• Unresectable tumor or patient deemed unfit for surgery
• T1-T4 (AJCC staging 8th edition), N0-N2-M0 (AJCC staging 8th edition), radiologically or pathologically suspect. N1 is defined as one to three affected lymph nodes typically involving the hilar, cystic duct, common bile duct, hepatic artery, posterior pancreatoduodenal, and portal vein lymph nodes. N2 is defined as four or more affected lymph nodes from the sites described for N1. Endoscopic ultrasound (EUS) is leading in identifying pathological lymph nodes compared to CT.
• In case of (underlying) liver cirrhosis: Child-Pugh A
• Age ≥ 18 years
• ECOG performance status 0-1
• Written informed consent for the translational part of the study

Inclusion criteria SBRT part of the study:

In addition to the criteria mentioned above, patients should meet the following criteria to be eligible for the treatment with SBRT:

• Measurable disease to be selected as a target on a computed tomography (CT) or magnetic resonance imaging (MRI) scan, according to RECIST 1.1 criteria
• Finished gemcitabine-based chemotherapy treatment, preferably 8 cycles. If less cycles are given, patients are still eligible for this study
• Bilirubin ≤3.0 times normal value, aspartate aminotransferase (AST)/alanine transaminase (ALT) ≤5 times ULN
• Platelets ≥ 50x10E9/ l, Leukocytes > 1.5x10E9/l, Hemoglobin (Hb) > 6 mmol/l
• Willing and able to comply to the follow-up schedule
• Able to start SBRT within 12 weeks after completion of chemotherapy and immuno-therapy (if applicable)
• Written informed consent for the SBRT part of the study

Exclusion criteria translational part of the study:

• Prior surgery or transplantation of the liver
• Tumor extension in stomach, colon, duodenum, pancreas or abdominal wall
• Ascites
• Prior radiotherapy to the liver
• Current pregnancy
• Affected lymph nodes outside the regions described in the inclusion criteria

Exclusion criteria SBRT part of the study:

Progression (local or distant) during or after chemotherapy

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Stereotactic body radiation therapy; Single-arm study	Radiation: Stereotactic body radiation therapy; SBRT will be delivered in 15 fractions of 4 to 4.5Gy (risk-adapted), one fraction each weekday for 3 weeks.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Local tumor control	Local tumor control is defined as time from inclusion to local radiological progression. Definition of progression is based on response evaluation criteria in solid tumors (RECIST) 1.1. In RECIST 1.1, response of a tumor to treatment is defined as either complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD).	42 months (maximum follow-up time)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression-free survival (PFS)	PFS is defined as time from inclusion until radiological progression. Definition of progression is based on RECIST 1.1.	42 months (maximum follow-up time)
Overall survival (OS)	OS is defined as time from inclusion until death from any cause.	42 months (maximum follow-up time)
Adverse events	Adverse events assessed by the Common Toxicity Criteria for Adverse Events (CTCAE) V.5.0	42 months (maximum follow-up time)
Quality of life (QoL) - EQ-5D-5L	Assessed by means of the EuroQol (EQ)-5D-5L (measure of health outcome in general population).	36 months
Quality of life (QoL) - QLQ-C30	Assessed by means of the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 (QoL specific for patients with cancer).	36 months
Quality of life (QoL) - QLQ-BIL21	Assessed by means of the supplementary module EORTC QLQ-BIL21 (specific for CCA and gallbladder cancer).	36 months
Biliary stent-related events (SRE)	The definition of SRE in this study is based on the definition used in the study by Lamarca et al. (https://doi.org/10.3748/wjg.v22.i26.6065). A SRE is defined as any one or more of the following: 1. any episode of jaundice which is considered significant enough for new stenting or medical treatment and is confirmed by radiological imaging to be associated with biliary dilatation; 2. any episode of infection which is clinically in keeping with cholangitis (bile duct infection) requiring antibiotic therapy; 3. bacteraemia with isolation in blood cultures of bacteria suspected to have originated in the biliary tract; and 4. any episode of cholecystitis or gallbladder perforation.	42 months (maximum follow-up time)

Collaborators and Investigators

• Sponsor: Erasmus Medical Center
• Collaborators: Dutch Cancer Society
• Investigators: Principal Investigator: Alejandra Méndez Romero, MD, PhD, Erasmus Medical Center

Study record dates

Study Major Dates

• Study Start (Actual): July 1, 2024
• Primary Completion (Estimated): December 1, 2027
• Study Completion (Estimated): March 1, 2028

Study Registration Dates

• First Submitted: July 1, 2024
• First Submitted That Met QC Criteria: July 9, 2024
• First Posted (Actual): July 10, 2024

Study Record Updates

• Last Update Posted (Actual): July 15, 2025
• Last Update Submitted That Met QC Criteria: July 10, 2025
• Last Verified: December 1, 2024

More Information

Terms related to this study

• Keywords: Stereotactic body radiation therapy; Klatskin tumor; Perihilar cholangiocarcinoma
• Additional Relevant MeSH Terms: Neoplasms; Neoplasms by Histologic Type; Neoplasms, Glandular and Epithelial; Adenocarcinoma; Carcinoma; Cholangiocarcinoma; Klatskin Tumor
• Other Study ID Numbers: NL86210.078.24

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No